Zoledronate synergises with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth

British Journal of Haematology

Volumn 130, Issue 4, 2005, Pages 558-560

  Segawa, Hidekazu ^a,b   Kimura, Shinya ^a   Kuroda, Junya ^a   Sato, Kiyoshi ^a   Yokota, Asumi ^a   Kawata, Eri ^a   Kamitsuji, Yuri ^a   Ashihara, Eishi ^a   Yuasa, Takeshi ^a   Fujiyama, Yoshihide ^b   Ottmann, Oliver G ^c   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Bisphosphonate; Imatinib mesylate; Prenylation; Primary leukaemic cells; Zoledronate

Indexed keywords

BCR ABL PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; IMATINIB; RAP1 PROTEIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOLECULAR CLONING; MONOTHERAPY; MOUSE; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRENYLATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; MOUSE MUTANT; MYELOID LEUKEMIA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIPHOSPHONATES; DRUG SYNERGISM; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE; MICE, SCID; MODELS, ANIMAL; NEOPLASM TRANSPLANTATION; PIPERAZINES; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 24944565348     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05648.x     Document Type: Article

References (8)

1. Center for Drug Evaluation and Research ( 2001) Zometa (zoledronic acid) injection. Pharmacology review(s), part 2 (p. 84), WWW document, available at: http://www.fda.gov/cder/foi/nda/2001/21-223_zormeta_pharmr_P2.pdf
2. Chen T. Berenson J. Vescio R. Swift R. Gilchick A. Goodin S. LoRusso P. Ma P. Ravera C. Deckert F. Schran H. Seaman J. Skerjanec A. ( 2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. Journal of Clinical Pharmacology, 42, 1228 1236.
3. Espanol I. Romagosa V. Berlanga J. Domingo A. Losa F. Heras L. Janariz J. ( 2004) Zoledronate-induced remission of acute panmyelosis with myelofibrosis. European Journal of Haematology, 73, 215 218.
4. Hiraga T. Williams P.J. Mundy G.R. Yoneda T. 2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Research, 61, 4418 4424.
5. Kimura S. Kuroda J. Segawa H. Sato K. Nogawa M. Yuasa T. Ottmann O.G. Maekawa T. ( 2004) Anti-proliferative efficacy of the third generation bisphosphonate zoledronic acid combined with other anti-cancer drugs in leukemic cell lines. International Journal of Hematology, 79, 37 43.
6. + leukemia activity of imatinib mesylate. Blood, 102, 2229 2235.
7. Sato M. Grasser W. Endo N. Akins R. Simmons H. Thompson D.D. Golub E. Rodan G.A. ( 1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investigation, 88, 2095 2105.
8. Wang L. Pearson K. Ferguson J.E. Clark R.E. ( 2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. British Journal of Haematology, 120, 990 999.